Sage Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Sage Therapeutics sono diminuiti a un tasso medio annuo di -9.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.3%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 27.4%.

Informazioni chiave

-9.6%

Tasso di crescita degli utili

-6.0%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	-27.4%
Rendimento del capitale proprio	-61.2%
Margine netto	-317.3%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Ripartizione dei ricavi e delle spese

Come Sage Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:SAGE Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	106	-338	217	-4
30 Jun 24	97	-446	242	0
31 Mar 24	91	-503	261	0
31 Dec 23	86	-541	275	0
30 Sep 23	11	-656	287	20
30 Jun 23	10	-592	270	0
31 Mar 23	9	-558	247	0
31 Dec 22	8	-533	228	0
30 Sep 22	6	-510	212	0
30 Jun 22	6	-503	199	0
31 Mar 22	6	-484	190	0
31 Dec 21	6	-458	183	0
30 Sep 21	1,114	642	185	0
30 Jun 21	1,114	666	172	0
31 Mar 21	1,113	637	167	0
31 Dec 20	1,114	606	197	0
30 Sep 20	7	-537	229	0
30 Jun 20	9	-612	282	0
31 Mar 20	9	-644	332	0
31 Dec 19	7	-680	346	0
30 Sep 19	5	-670	336	0
30 Jun 19	2	-613	302	0
31 Mar 19	91	-462	256	0
31 Dec 18	90	-373	201	0
30 Sep 18	90	-284	145	0
30 Jun 18	90	-235	108	0
31 Mar 18	0	-288	79	-45
31 Dec 17	0	-270	63	0
30 Sep 17	0	-257	58	42
30 Jun 17	0	-221	51	71
31 Mar 17	0	-185	45	142
31 Dec 16	0	-159	39	0
30 Sep 16	0	-132	33	99
30 Jun 16	0	-118	31	88
31 Mar 16	0	-108	28	80
31 Dec 15	0	-94	25	69
30 Sep 15	0	-78	20	58
30 Jun 15	0	-64	17	47
31 Mar 15	0	-47	12	33
31 Dec 14	0	-36	10	24
30 Sep 14	0	-29	7	20
30 Jun 14	0	-24	6	16
31 Mar 14	0	-21	5	16

Guadagni di qualità: SAGE al momento non è redditizia.

Margine di profitto in crescita: SAGE al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: SAGE non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 9.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di SAGE nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: SAGE non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: SAGE ha un Return on Equity negativo ( -61.18% ), in quanto al momento non è redditizio.

Sage Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

CNS Drug Development: Same As It Ever Was

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%